Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) had its price target cut by JPMorgan Chase & Co. from €51.00 ($52.58) to €23.00 ($23.71) in a research note released on Monday, The Fly reports.
Other analysts also recently issued reports about the company. StockNews.com downgraded Fresenius Medical Care AG & Co. KGaA from a strong-buy rating to a buy rating in a report on Friday, July 15th. Truist Financial decreased their target price on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a hold rating for the company in a research report on Wednesday, June 22nd. UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a buy rating to a neutral rating in a research note on Friday, July 29th. DZ Bank lowered Fresenius Medical Care AG & Co. KGaA from a buy rating to a hold rating in a research report on Friday, July 29th. Finally, Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from an underperform rating to a buy rating and boosted their price target for the stock from $30.30 to $33.70 in a research report on Monday, June 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Hold and a consensus price target of $49.01.
Get Fresenius Medical Care AG & Co. KGaA alerts:Fresenius Medical Care AG & Co. KGaA Trading Down 0.4 %
FMS stock opened at $18.44 on Monday. The company has a market cap of $10.81 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 0.85 and a beta of 1.02. The company has a quick ratio of 0.93, a current ratio of 1.18 and a debt-to-equity ratio of 0.47. The business has a fifty day simple moving average of $24.60 and a 200-day simple moving average of $29.72. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $18.16 and a 52 week high of $40.85.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.38 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.08. The business had revenue of $5.10 billion during the quarter, compared to the consensus estimate of $4.97 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.70% and a net margin of 4.42%. On average, equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.79 EPS for the current year.Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA
Institutional investors have recently made changes to their positions in the business. Tcwp LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $44,000. SRS Capital Advisors Inc. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 36.0% in the 1st quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company's stock valued at $52,000 after purchasing an additional 409 shares in the last quarter. Creative Financial Designs Inc. ADV bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $67,000. GHP Investment Advisors Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $72,000. Finally, Signaturefd LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 26.4% in the 1st quarter. Signaturefd LLC now owns 2,190 shares of the company's stock valued at $74,000 after acquiring an additional 458 shares during the last quarter. 4.73% of the stock is owned by institutional investors and hedge funds.
About Fresenius Medical Care AG & Co. KGaA
(Get Rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Articles
- Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- 3 Hotel Stocks to Consider Checking into After Earnings
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- Time To Take A Serious Look At Nikola Stock As Production Starts
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.